IL1B and Hepatic fibrosis: Similarly, the 15 mg/kg dose exhibited greater efficacy, reducing IL-6 and IL-1β levels by 54.62% and 47.06%, respectively, and enhancing IL-10 levels by 227.27% as compared to TAA-induced liver fibrosis group (Fig. 3A–C).